The associate professor at The Ohio State University Comprehensive Cancer Center explained the goals for the future of the CAR T-cell therapy data in patients with DLBCL.
Authors indicated that reductions in smoking and treatment breakthroughs have led to this steady decline.
Largest analysis of data to date shows no link between use of talc powder and rate of ovarian cancer incidence
This study indicated the necessity for healthcare providers to initiate discussions on the experience of hearing loss for cancer survivors, as well as care options and interventions.
The FDA approved pembrolizumab for the treatment of patients with BCG–unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in-situ with or without papillary tumors who are ineligible for or chose to not undergo cystectomy.
Results of this phase III trial could change the current standard of care for treating nonseminomatous or combined germ cell tumors of the testis.
Researchers found that patients in this study used a number of unsafe practices to limit opioid use, including turning to other substances to avoid “harder medicines.”
The medical oncologist from the John Theurer Cancer Center noted the importance of real-world data in determining potentially different toxicity profiles in these BTK-inhibitors.
Researchers used next-generation sequencing to analyze the landscape of neoantigens, identifying neoantigen-specific immune cells triggered by immunotherapy.
Researchers suggest that improved communication at the facility-level and health-system level could significantly improve the care of nursing home residents with poor-prognosis cancer.
The approach was created by the University of Michigan Rogel Cancer Center to limit variability and investigator bias.
Though physical activity guidelines are largely based on chronic diseases like cardiovascular disease and diabetes, these data suggest they are important to cancer prevention as well.
Compared with anti-PD-L1, anti-PD-1 offered a comparable safety profile while also exhibiting favorable survival outcomes in patients with solid tumors.
The study found that patients who were randomized to receive avelumab and best supportive care lived significantly longer than those who only received best supportive care.
The study evaluating itacitinib in combination with corticosteroids in patients with treatment-naïve acute graft-versus-host disease did not produce statistically significant results.